Our team’s support of the ESP program includes managing the increased receipt of electronic submissions, ensuring compliance with the eCTD 4.0 guidance for Industry, and providing FDA with technical expertise to respond to the planned and potential upcoming changes required to further enhance the program and ensure the timely processing of submissions for scientific reviewers to quickly to meet and exceed required timeframes to complete their reviews within the Prescription Drug User Fee Act (PDUFA) guidelines.